Ensayos clínicos A continuación se enumeran ensayos clínicos actuales.66 estudios en Gastroenterología y Hepatología (estudios abiertos únicamente). Filtrar esta lista de estudios según la ubicación, el estado del estudio y más. Mayo Clinic Inflammatory Bowel Disease Repository Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this research study is to collect clinical information and human samples from patients with IBD. The data collected will be used to create an organized, accessible resource of human samples for biological research in IBD. A Study of Intratumoral Injection of Autologous Dendritic Cells after High-Dose Conformal External Beam Radiotherapy in Patients with Unresectable Liver Cancer Rochester, Minn. The primary purpose of the pilot study is to evaluate the safety and tolerability of an autologous dendritic cells (DC) vaccine delivered by intra-tumoral injection in patients with primary liver cancer treated with high-dose conformal external beam radiotherapy (EBRT). The primary purpose of the phase II study is to estimate the progression-free survival rate at 2 years post-registration to see if treatment is efficacious compared to historical data. A Study to Develop a Biorepository of Blood Samples from Cancer Patients Participating in the Gemini (IRB 19-006717) Protocol Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to develop a biorepository of blood samples from cancer patients participating in the Gemini (IRB 19-006717) protocol. These samples will be used for future biomarker discovery and other translational studies. A Study to Evaluate the Therapeutic Effectiveness of Rifaximin in Diabetic Gastroparesis Patients Using Bloating as the Primary Endpoint Jacksonville, Fla. The primary purpose of this study is to prospectively assess symptoms of bloating (severity, prevalence) in patients with diabetic gastroparesis. Evaluating Markers which Might be a Predictor of Pancreatic Cancer or Precancer by Analyzing the Secretions (fluid) from a Pancreatic cyst Rochester, Minn. The purpose of this study is to evaluate molecular markers which might be a predictor of pancreatic cancer or precancer by analyzing the secretions (fluid) from a pancreatic cyst, pancreas fluid and tissue from a resected pancreatic cyst. Symptoms During a Gastric Emptying Study Rochester, Minn. To understand the utility of measuring stomach emptying, symptoms during a stomach emptying, and blood markers of body metabolism. Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma Rochester, Minn., Mankato, Minn., Jacksonville, Fla., Eau Claire, Wis., Austin, Minn., Scottsdale/Phoenix, Ariz. This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease. In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls Jacksonville, Fla. The purpose of this study is to evaluate the impact of the location of SQ Nivo administration, at the infusion center or in the home, on patient preference and acceptability, safety, patient reported outcomes (PROs), and clinical outcomes. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Rochester, Minn., Scottsdale/Phoenix, Ariz. In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy. The Olmsted NAFLD Epidemiology Study (TONES) Rochester, Minn. About this study Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and a major public health issue in the US. It is estimated to affect 1 in 4 adults and it is most commonly found in people who are overweight or obese. Because it is a silent disease (without symptoms until end stage) and the lab tests can be normal, it can be missed in early stages. The fat in the liver can lead to inflammation and eventually scar deposition, which can progress to cirrhosis, liver cancer and need for liver transplantation. This study aims to assess how common this disease is in Olmsted County, what markers can identify the disease early to prevent progression to cirrhosis and what other medical problems occur in people with NAFLD in addition to the liver complications. We plan to enroll a large number of adults, assess their liver with state-of-the-art tests available at Mayo Clinic and follow them over several years to monitor for disease progression and other health complications. The ultimate goal of the study is to identify new markers that predict presence of fatty liver and poor health outcomes, in order to improve population health in the community. Participation eligibility Participants will be identified from the Olmsted County population age 18 or older. Inclusion criteria: 1. Adults age 18 years or older 2. Olmsted County residents at the time of study entry Exclusion criteria: 1. Pediatric population (age<18) 2. Unwilling to participate or unable to consent 3. Known liver disease other than NAFLD at the time of survey 4. Pregnant women 5. Alcohol use in excess (14 drinks or more per week for women and 21 drinks or more per week for men) Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 44 Ir a página 55 Ir a página 66 Ir a página 77 SiguientePróxima página Solicite una consulta Conocimientos y categoríasInvestigación July 19, 2025 Comparte en: FacebookTwitter U.S. News & World Report reconoce a Mayo Clinic de Rochester, Minnesota, como el mejor hospital del país para gastroenterología y cirugía gastrointestinal en el período 2024-2025. Obtén más información sobre este gran honor Gastroenterología y HepatologíaPágina inicialdel departamentoSeccionesPanorama generalAnálisis y procedimientosEnfermedades tratadasMédicosMédicos por sede y especialidadGrupos por especialidadConocimientos y categoríasEnsayos clínicosInvestigaciónHistorias de pacientesCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaPanorama generalMédicosMédicos por sede y especialidadGrupos por especialidadConocimientos y categoríasInvestigaciónCostos y seguroRemisiones ORG-20308333 Centros y departamentos médicos Gastroenterología y Hepatología